By: Benzinga
UPDATE: Canaccord Lowers PT on AngioDynamics on Continued Tepid Business Trends
In a report published Friday, Canaccord Genuity reiterated its Hold rating on AngioDynamics (NASDAQ: ANGO ), but slightly lowered its price target from $12.50 to $11.50. Canaccord Genuity noted, “Coming out of ANGO's January analyst meeting, we expressed skepticism about growth prospects for the company's products – namely in Peripheral
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here